Velsera Announces Appointment of Jamie Littlejohns as New Chief Executive Officer

Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024. Jamie is set to succeed Hans Cobben, who has served as the interim CEO and will revert to his position as Chairman of the Board at Velsera.

Jamie joins Velsera from his previous role at McKinsey, where he was a Partner and led McKinsey's European Healthcare & Life Science Private Equity Practice. He has worked in Healthcare and Life Sciences since 2010 across Europe, the US and Australia and has developed expertise in supporting investor-backed health & life science tech companies on their scale-up journeys. Although new to Velsera in a full-time capacity, Jamie has been part of Velsera's journey since early 2022 through his support in an external advisory capacity.

In his own words, Jamie says, "I am thrilled to be joining the wonderful team at Velsera. I firmly believe that Velsera's unique combination of expertise and capabilities has the power to transform precision medicine - accelerating the pace of drug discovery; improving access to novel diagnostics and therapeutics; and making better, more precise decisions about patient care. I look forward to helping steer Velsera on the next phase of their growth journey and I am excited to partner with our customers to make significant advances in the field of precision medicine."

Furthermore, Hans Cobben, the Chairman of the Board, articulated the board's support for Jamie's appointment, stating, "We are delighted that Jamie has agreed to join Velsera as our incoming CEO. He brings a wealth of experience working with similar companies to accelerate their growth trajectories and realize their full potential. Furthermore, his prior experience with both Summa and Velsera enables him to hit the ground running, providing continuity whilst injecting his unique energy into Velsera. I eagerly anticipate our continued expansion and success."

For more information about Velsera and its leadership, visit www.velsera.com.

About Velsera

Velsera's mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help doctors and drug hunters make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2022 as a result of the merger of Seven Bridges, PierianDx and UgenTec, and operates in the US, Europe and Asia.